All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

Clinical implications of the ODAC vote in favor of polatuzumab vedotin for untreated DLBCL

Apr 17, 2023

Following a U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting, the Lymphoma Hub was pleased to speak Grzegorz Nowakowski, Mayo Clinic, Rochester, US. We asked, What are the clinical implications of the ODAC vote for a favorable benefit/risk profile of polatuzumab vedotin for untreated diffuse large B-cell lymphoma (DLBCL)? 

Clinical implications of the ODAC vote in favor of polatuzumab vedotin for untreated DLBCL.

Nowakowski discusses findings from the phase III POLARIX study (GO39942; NCT03274492) comparing polatuzumab vedotin plus R-CHP (rituximab, cyclophosphamide, doxorubicin, and prednisolone) with the current standard of care, R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone), in patients with previously untreated DLBCL. Nowakowski summarizes the data on progression-free survival, overall survival, and toxicities, referring to the heterogeneity of patients in this study. Finally, Nowakowski discusses polatuzumab vedotin in the context of current standard of care treatments and the global clinical impact this may have.

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Your opinion matters

What kind of 1L DLBCL patients should now be treated with Pola-R-CHP (choose all options that apply)?
4 votes - 1 day left ...


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox